Enovis Corporation (ENOV) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $29.15 (-0.38%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Mike Matson | Needham | $52.00 | +78.4% |
| Jan 6, 2026 | Ryan Zimmerman | BTIG | $41.00 | +40.7% |
| Jan 5, 2026 | Danielle Antalffy | UBS | $50.00 | +71.5% |
| Nov 6, 2024 | Mike Matson | Needham | $65.00 | +123.0% |
| Jul 2, 2024 | Vijay Kumar | Evercore ISI | $62.00 | +112.7% |
| May 3, 2024 | Jeff Johnson | Robert W. Baird | $64.00 | +119.6% |
| Dec 15, 2023 | Mike Matson | Needham | $70.00 | +140.1% |
| May 12, 2023 | Vik Chopra | Wells Fargo | $67.00 | +129.8% |
Top Analysts Covering ENOV
ENOV vs Sector & Market
| Metric | ENOV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 7 | 8 | 19 |
| Target Upside | +38.7% | +16366.1% | +18.0% |
| P/E Ratio | -1.12 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.33B | $2.34B | $2.36B | 8 |
| 2027-03-31 | $605M | $607M | $611M | 2 |
| 2027-06-30 | $620M | $623M | $626M | 2 |
| 2027-09-30 | $596M | $599M | $602M | 2 |
| 2027-12-31 | $645M | $648M | $651M | 2 |
| 2028-03-31 | $632M | $635M | $639M | 1 |
| 2028-06-30 | $643M | $646M | $650M | 1 |
| 2028-09-30 | $628M | $630M | $634M | 1 |
| 2028-12-31 | $673M | $676M | $680M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.55 | $3.58 | $3.61 | 6 |
| 2027-03-31 | $0.94 | $0.94 | $0.95 | 1 |
| 2027-06-30 | $0.99 | $1.00 | $1.00 | 1 |
| 2027-09-30 | $0.95 | $0.96 | $0.97 | 1 |
| 2027-12-31 | $1.10 | $1.10 | $1.11 | 1 |
| 2028-03-31 | $1.19 | $1.19 | $1.20 | 2 |
| 2028-06-30 | $1.17 | $1.17 | $1.18 | 2 |
| 2028-09-30 | $1.03 | $1.03 | $1.04 | 2 |
| 2028-12-31 | $1.13 | $1.13 | $1.14 | 2 |
Frequently Asked Questions
What is the analyst consensus for ENOV?
The consensus among 7 analysts covering Enovis Corporation (ENOV) is Buy with an average price target of $37.67.
What is the highest price target for ENOV?
The highest price target for ENOV is $70.00, set by Mike Matson at Needham on 2023-12-15.
What is the lowest price target for ENOV?
The lowest price target for ENOV is $41.00, set by Ryan Zimmerman at BTIG on 2026-01-06.
How many analysts cover ENOV?
7 analysts have issued ratings for Enovis Corporation in the past 12 months.
Is ENOV a buy or sell right now?
Based on 7 analyst ratings, ENOV has a consensus rating of Buy (2.00/5) with a +38.7% upside to the consensus target of $37.67.
What are the earnings estimates for ENOV?
Analysts estimate ENOV will report EPS of $3.58 for the period ending 2026-12-31, with revenue estimated at $2.34B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.